 Lu Huang
Concepts (179)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 14 | 2024 | 291 | 4.470 |
Why?
| | Eosinophils | 4 | 2016 | 44 | 1.880 |
Why?
| | Tuberculosis | 8 | 2024 | 152 | 1.860 |
Why?
| | Macrophages, Alveolar | 4 | 2025 | 30 | 1.740 |
Why?
| | Macrophages | 11 | 2022 | 379 | 1.520 |
Why?
| | Trichinellosis | 4 | 2017 | 5 | 1.460 |
Why?
| | Host-Pathogen Interactions | 12 | 2025 | 144 | 1.380 |
Why?
| | Lung | 8 | 2024 | 509 | 1.240 |
Why?
| | Tuberculosis, Pulmonary | 5 | 2024 | 111 | 1.220 |
Why?
| | Trichinella spiralis | 4 | 2017 | 4 | 1.090 |
Why?
| | Host-Parasite Interactions | 2 | 2016 | 17 | 1.020 |
Why?
| | Neutrophil Activation | 1 | 2024 | 13 | 0.900 |
Why?
| | Antitubercular Agents | 4 | 2021 | 107 | 0.830 |
Why?
| | Neutrophils | 1 | 2024 | 147 | 0.810 |
Why?
| | Animals | 30 | 2025 | 13505 | 0.800 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 87 | 0.770 |
Why?
| | Mice | 21 | 2025 | 5949 | 0.760 |
Why?
| | Bacterial Infections | 1 | 2022 | 101 | 0.730 |
Why?
| | Mice, Inbred C57BL | 14 | 2024 | 1884 | 0.690 |
Why?
| | Leishmaniasis, Cutaneous | 3 | 2015 | 15 | 0.630 |
Why?
| | Immunity, Innate | 2 | 2017 | 117 | 0.630 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 87 | 0.610 |
Why?
| | Eosinophilia | 2 | 2016 | 36 | 0.600 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 42 | 0.600 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 38 | 0.590 |
Why?
| | Granuloma | 1 | 2018 | 47 | 0.580 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 146 | 0.580 |
Why?
| | Interleukin-4 | 3 | 2018 | 44 | 0.570 |
Why?
| | Tuberculosis Vaccines | 1 | 2017 | 2 | 0.570 |
Why?
| | T-Lymphocytes | 1 | 2020 | 340 | 0.560 |
Why?
| | Helminthiasis | 1 | 2016 | 2 | 0.520 |
Why?
| | Interleukin-10 | 3 | 2024 | 84 | 0.520 |
Why?
| | Immunotherapy | 1 | 2017 | 244 | 0.480 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 24 | 0.470 |
Why?
| | Larva | 1 | 2014 | 32 | 0.460 |
Why?
| | Lipopeptides | 1 | 2015 | 62 | 0.460 |
Why?
| | Nitric Oxide | 2 | 2014 | 249 | 0.420 |
Why?
| | Interferon-gamma | 4 | 2024 | 180 | 0.400 |
Why?
| | Mice, Knockout | 5 | 2024 | 879 | 0.360 |
Why?
| | Mitochondria | 2 | 2025 | 430 | 0.360 |
Why?
| | Disease Models, Animal | 5 | 2025 | 1478 | 0.340 |
Why?
| | Ovary | 2 | 2021 | 107 | 0.330 |
Why?
| | Phagocytes | 2 | 2019 | 11 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2024 | 164 | 0.300 |
Why?
| | Fatty Acids | 2 | 2019 | 149 | 0.280 |
Why?
| | Monocytes | 2 | 2018 | 130 | 0.280 |
Why?
| | Hypertension | 2 | 2024 | 565 | 0.280 |
Why?
| | Transcription, Genetic | 3 | 2018 | 378 | 0.280 |
Why?
| | Cell Proliferation | 4 | 2025 | 1023 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 132 | 0.250 |
Why?
| | Q Fever | 1 | 2025 | 16 | 0.240 |
Why?
| | Dendritic Cells | 3 | 2015 | 136 | 0.230 |
Why?
| | Coxiella burnetii | 1 | 2025 | 32 | 0.230 |
Why?
| | Immunity | 2 | 2022 | 39 | 0.230 |
Why?
| | Interleukin-1 | 1 | 2025 | 107 | 0.230 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2025 | 20 | 0.230 |
Why?
| | Rats | 3 | 2015 | 3220 | 0.230 |
Why?
| | Cytokines | 2 | 2019 | 623 | 0.220 |
Why?
| | Vacuoles | 2 | 2025 | 24 | 0.220 |
Why?
| | Humans | 14 | 2025 | 52483 | 0.210 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 44 | 0.210 |
Why?
| | Homeodomain Proteins | 1 | 2024 | 80 | 0.210 |
Why?
| | Chlamydia muridarum | 1 | 2024 | 40 | 0.210 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 100 | 0.210 |
Why?
| | Herpesvirus 8, Human | 1 | 2025 | 98 | 0.210 |
Why?
| | Chlamydia Infections | 1 | 2024 | 76 | 0.200 |
Why?
| | Cells, Cultured | 3 | 2025 | 1567 | 0.200 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2020 | 54 | 0.200 |
Why?
| | Th1 Cells | 2 | 2024 | 55 | 0.190 |
Why?
| | Interleukin-17 | 2 | 2020 | 35 | 0.190 |
Why?
| | Luminescent Proteins | 1 | 2021 | 54 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 4 | 0.170 |
Why?
| | Isoniazid | 2 | 2018 | 36 | 0.160 |
Why?
| | Rifampin | 2 | 2018 | 63 | 0.160 |
Why?
| | Metabolism | 1 | 2019 | 25 | 0.160 |
Why?
| | Microbial Viability | 1 | 2019 | 32 | 0.160 |
Why?
| | Phagosomes | 1 | 2019 | 19 | 0.160 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2021 | 187 | 0.150 |
Why?
| | Granuloma, Respiratory Tract | 1 | 2018 | 1 | 0.150 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2018 | 10 | 0.150 |
Why?
| | Aging | 2 | 2021 | 701 | 0.150 |
Why?
| | Bystander Effect | 1 | 2018 | 25 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2018 | 88 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 67 | 0.140 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 93 | 0.140 |
Why?
| | Glycolysis | 1 | 2018 | 73 | 0.140 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 235 | 0.140 |
Why?
| | Immunomodulation | 1 | 2017 | 38 | 0.140 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 14 | 0.140 |
Why?
| | Cell Cycle | 1 | 2018 | 230 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 326 | 0.130 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 312 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 1222 | 0.130 |
Why?
| | Drug Resistance, Bacterial | 1 | 2016 | 82 | 0.120 |
Why?
| | Bacterial Proteins | 1 | 2019 | 361 | 0.120 |
Why?
| | Signal Transduction | 2 | 2020 | 1671 | 0.120 |
Why?
| | Influenza A Virus, H3N8 Subtype | 1 | 2015 | 1 | 0.120 |
Why?
| | RNA, Messenger | 1 | 2018 | 1132 | 0.120 |
Why?
| | Injections | 1 | 2015 | 61 | 0.120 |
Why?
| | Eosinophil Major Basic Protein | 1 | 2014 | 1 | 0.120 |
Why?
| | Eosinophil Peroxidase | 1 | 2014 | 1 | 0.120 |
Why?
| | Antibodies, Helminth | 1 | 2014 | 4 | 0.120 |
Why?
| | Immunization, Passive | 1 | 2014 | 29 | 0.120 |
Why?
| | Models, Biological | 1 | 2018 | 735 | 0.110 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2014 | 62 | 0.110 |
Why?
| | Trachea | 1 | 2015 | 57 | 0.110 |
Why?
| | Leukocyte Count | 1 | 2014 | 73 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 405 | 0.110 |
Why?
| | Arginase | 1 | 2014 | 38 | 0.110 |
Why?
| | Coinfection | 1 | 2014 | 47 | 0.110 |
Why?
| | Genetic Variation | 1 | 2015 | 230 | 0.110 |
Why?
| | Plasma Cells | 1 | 2014 | 239 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 2 | 2024 | 34 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 807 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2015 | 979 | 0.100 |
Why?
| | Sodium | 2 | 2024 | 95 | 0.100 |
Why?
| | Chronic Disease | 1 | 2014 | 586 | 0.090 |
Why?
| | Leishmaniasis Vaccines | 1 | 2010 | 1 | 0.090 |
Why?
| | Leishmania major | 1 | 2010 | 10 | 0.090 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2010 | 43 | 0.080 |
Why?
| | Pyrazinamide | 1 | 2009 | 8 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 9 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2014 | 804 | 0.080 |
Why?
| | Vaccination | 1 | 2010 | 298 | 0.070 |
Why?
| | Female | 4 | 2024 | 28171 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1105 | 0.070 |
Why?
| | Cell Line | 3 | 2016 | 1030 | 0.070 |
Why?
| | Oxidative Phosphorylation | 1 | 2025 | 46 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 220 | 0.060 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2024 | 6 | 0.060 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 256 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2024 | 205 | 0.050 |
Why?
| | Sodium Chloride Symporters | 1 | 2022 | 7 | 0.050 |
Why?
| | Kidney Tubules, Distal | 1 | 2022 | 14 | 0.050 |
Why?
| | Heme | 1 | 2021 | 21 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2021 | 40 | 0.050 |
Why?
| | Ovulation | 1 | 2021 | 4 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2024 | 665 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 990 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 81 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2021 | 86 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2025 | 1470 | 0.040 |
Why?
| | RNA | 1 | 2020 | 168 | 0.040 |
Why?
| | Male | 1 | 2020 | 26761 | 0.040 |
Why?
| | Base Sequence | 1 | 2020 | 640 | 0.040 |
Why?
| | Apoptosis | 1 | 2025 | 1119 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2019 | 37 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2018 | 24 | 0.040 |
Why?
| | Chemokine CCL3 | 1 | 2018 | 13 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 69 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2021 | 478 | 0.040 |
Why?
| | HeLa Cells | 1 | 2018 | 265 | 0.040 |
Why?
| | Lymphocytes | 1 | 2018 | 153 | 0.040 |
Why?
| | Transcriptome | 1 | 2020 | 370 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 406 | 0.040 |
Why?
| | Thymocytes | 1 | 2017 | 2 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 23 | 0.030 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 459 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2016 | 39 | 0.030 |
Why?
| | Sialic Acids | 1 | 2015 | 3 | 0.030 |
Why?
| | Virus Attachment | 1 | 2015 | 3 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2015 | 4 | 0.030 |
Why?
| | Viral Tropism | 1 | 2015 | 5 | 0.030 |
Why?
| | Adaptation, Biological | 1 | 2015 | 11 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2015 | 26 | 0.030 |
Why?
| | Horses | 1 | 2015 | 49 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 180 | 0.030 |
Why?
| | Phylogeny | 1 | 2015 | 231 | 0.030 |
Why?
| | Protein Binding | 1 | 2015 | 667 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2010 | 6 | 0.020 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2010 | 30 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 121 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2010 | 172 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2009 | 27 | 0.020 |
Why?
| | Mutation | 1 | 2015 | 1347 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 278 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 612 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 399 | 0.020 |
Why?
| | Skin | 1 | 2010 | 422 | 0.020 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|